Abstract
Malegaonkar et al. have raised concerns on two issues with reference to our paper entitled '4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial' in the letter 'False equivalence of four month and six-month ATT regimen: A case of comparing apples and oranges'. They have flagged the use of an intermittent 6-month regimen as the control arm, and questioned the rationality of using moxifloxacin in the treatment of drug-susceptible tuberculosis (TB).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Tropical medicine & international health : TM & IH
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
